Modeling the effect of chemotaxis on glioblastoma tumor progression
- 8 February 2011
- journal article
- research article
- Published by Wiley in AIChE Journal
- Vol. 57 (3) , 778-792
Abstract
Tumor progression depends on the intricate interplay between biological processes that span the molecular and macroscopic scales. A mathematical agent‐based model is presented to describe the 3‐D (three‐dimensional) progression of a brain tumor type (i.e., glioblastoma multiforme) as the collective behavior of individual tumor cells whose fate is determined by intracellular signaling pathways (i.e., MAPK pathway) that are governed by the temporal‐spatial distribution of key biochemical cues (i.e., growth factors, nutrients). The model is used to investigate how tumor growth and invasiveness depend on the response of migrating tumor cells to chemoattractants. Simulation results suggest that individual cell sensitivity to chemical gradients is necessary to generate in silico tumors with the irregular shape and diffusive tumor‐stroma interface characteristic of glioblastomas. In addition, vascular network damage influences tumor growth and invasiveness. The results quantitatively recapitulate the central role that nutrient availability and signaling proteins have on tumor invasive properties. © 2010 American Institute of Chemical Engineers AIChE J, 2011Keywords
This publication has 89 references indexed in Scilit:
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant GliomasClinical Cancer Research, 2008
- Feasibility of Using Bevacizumab With Radiation Therapy and Temozolomide in Newly Diagnosed High-Grade GliomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Malignant astrocytic glioma: genetics, biology, and paths to treatmentGenes & Development, 2007
- Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain MicroenvironmentJNCI: Journal of the National Cancer Institute, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Glioma Therapy in AdultsThe Neurologist, 2006
- Ionizing Radiation Enhances Matrix Metalloproteinase-2 Secretion and Invasion of Glioma Cells through Src/Epidermal Growth Factor Receptor–Mediated p38/Akt and Phosphatidylinositol 3-Kinase/Akt Signaling PathwaysCancer Research, 2006
- EphB2/R-Ras Signaling Regulates Glioma Cell Adhesion, Growth, and InvasionThe American Journal of Pathology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005